Hayek Kallen Investment Management Has $5.21 Million Stake in Johnson & Johnson (JNJ)

Hayek Kallen Investment Management lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 3.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,050 shares of the company’s stock after selling 1,372 shares during the period. Johnson & Johnson makes up 3.6% of Hayek Kallen Investment Management’s portfolio, making the stock its 5th biggest position. Hayek Kallen Investment Management’s holdings in Johnson & Johnson were worth $5,207,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A boosted its stake in shares of Johnson & Johnson by 2.2% in the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock valued at $8,113,000 after purchasing an additional 1,321 shares during the period. Welch & Forbes LLC boosted its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after purchasing an additional 6,730 shares during the period. Janney Montgomery Scott LLC boosted its stake in shares of Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after purchasing an additional 3,533 shares during the period. Oliver Luxxe Assets LLC boosted its stake in shares of Johnson & Johnson by 12.7% in the second quarter. Oliver Luxxe Assets LLC now owns 17,538 shares of the company’s stock valued at $2,320,000 after purchasing an additional 1,972 shares during the period. Finally, Sitrin Capital Management LLC boosted its stake in shares of Johnson & Johnson by 1.6% in the second quarter. Sitrin Capital Management LLC now owns 48,986 shares of the company’s stock valued at $6,480,000 after purchasing an additional 792 shares during the period. 65.70% of the stock is owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) opened at $140.55 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52-week low of $110.76 and a 52-week high of $144.35. The stock has a market cap of $377,590.00, a PE ratio of 24.40, a PEG ratio of 2.65 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the firm posted $1.68 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.39%. Johnson & Johnson’s payout ratio is currently 58.33%.

Several research analysts have recently weighed in on the stock. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday, September 18th. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research note on Wednesday, October 18th. Citigroup increased their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price objective for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Finally, Argus increased their price objective on shares of Johnson & Johnson from $145.00 to $165.00 and gave the company a “positive” rating in a research note on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $145.52.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/01/05/hayek-kallen-investment-management-has-5-21-million-stake-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply